Recce Ltd is pleased to announce that P.R. China Application 200880124515.5 has been granted;
patent number ZL200880124515.5 (with payment of maintenance fees) is now official and active until an expiry date of 06 August 2028. This patent relates to Recce’s patent Family 1 in which the Company has previously announced the grant of patents, of similar expiry dates, in USA, Europe, Japan and Australia,respectively.
Combined, these patents give Recce a manufacturing and marketing monopoly or RECCE antibiotics – within approximately 80% of the world pharmaceutical markets.
RCE Price at posting:
29.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)